Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05665088 · ClinicalTrials.gov registry record · Phase 3
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
A Phase 3 study, sponsored by BioXcel Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT05665088 is a Phase 3 study that was terminated before completion, run by BioXcel Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT05665088, a Phase 3 study, was terminated before completion, sponsored by BioXcel Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed \[PRN\]), for a maximum of 168 doses within a 12-week treatment period.
Interventions
- DRUG Matching Placebo
- DRUG BXCL501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2023-09-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05665088
The ClinicalTrials.gov registry entry for NCT05665088 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioXcel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT05665088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05665088 about?
NCT05665088 is a clinical study titled "Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)". A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed \[PRN\]), for a maximum of 168 doses within a 12-week treatment period.
What is the current status of trial NCT05665088?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2022-12-14. Estimated completion is 2023-09-11.
What interventions are being tested in trial NCT05665088?
The interventions under investigation include: Matching Placebo (DRUG), BXCL501 (DRUG).
Who is sponsoring clinical trial NCT05665088?
This trial is sponsored by BioXcel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.